A detailed history of Envestnet Portfolio Solutions, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Envestnet Portfolio Solutions, Inc. holds 11,467 shares of HALO stock, worth $652,586. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,467
Previous 9,451 21.33%
Holding current value
$652,586
Previous $384,000 56.25%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

BUY
$37.81 - $52.4 $76,224 - $105,638
2,016 Added 21.33%
11,467 $600,000
Q1 2024

May 06, 2024

SELL
$33.68 - $41.95 $54,965 - $68,462
-1,632 Reduced 14.73%
9,451 $384,000
Q4 2023

Feb 07, 2024

SELL
$33.32 - $42.1 $46,448 - $58,687
-1,394 Reduced 11.17%
11,083 $409,000
Q3 2023

Nov 13, 2023

BUY
$36.46 - $44.03 $454,911 - $549,362
12,477 New
12,477 $476,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.93B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Envestnet Portfolio Solutions, Inc. Portfolio

Follow Envestnet Portfolio Solutions, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Portfolio Solutions, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Portfolio Solutions, Inc. with notifications on news.